Carole Huntsman Sells 419 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) insider Carole Huntsman sold 419 shares of the company’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $431.94, for a total transaction of $180,982.86. Following the completion of the transaction, the insider owned 12,692 shares in the company, valued at approximately $5,482,182.48. The trade was a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Carole Huntsman also recently made the following trade(s):

• On Monday, January 26th, Carole Huntsman sold 910 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $493.78, for a total transaction of $449,339.80.

Madrigal Pharmaceuticals Price Performance

Madrigal Pharmaceuticals stock opened at $432.83 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77. The stock has a market cap of $9.93 billion, a price-to-earnings ratio of -33.63 and a beta of -0.97. The firm has a 50-day moving average of $492.64 and a two-hundred day moving average of $487.47. Madrigal Pharmaceuticals, Inc. has a 1 year low of $265.00 and a 1 year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The company had revenue of $321.08 million for the quarter, compared to analysts’ expectations of $310.36 million. During the same period last year, the business posted ($2.71) earnings per share. The business’s revenue was up 210.8% compared to the same quarter last year. On average, research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Institutional Trading of Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. AlphaQuest LLC increased its position in Madrigal Pharmaceuticals by 412.5% during the 2nd quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 66 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Madrigal Pharmaceuticals in the second quarter valued at about $428,000. Teacher Retirement System of Texas boosted its holdings in Madrigal Pharmaceuticals by 9.6% in the second quarter. Teacher Retirement System of Texas now owns 3,860 shares of the biopharmaceutical company’s stock worth $1,168,000 after acquiring an additional 338 shares in the last quarter. Spire Wealth Management boosted its holdings in Madrigal Pharmaceuticals by 150.0% in the second quarter. Spire Wealth Management now owns 250 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 150 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Madrigal Pharmaceuticals by 46.3% during the second quarter. Bank of New York Mellon Corp now owns 88,943 shares of the biopharmaceutical company’s stock worth $26,918,000 after acquiring an additional 28,154 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals News Summary

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright increased their price target on Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the stock a “buy” rating in a research report on Friday, November 21st. The Goldman Sachs Group restated a “buy” rating and set a $571.00 price target on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 14th. UBS Group set a $900.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Friday, December 19th. Finally, Citigroup reiterated an “outperform” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Madrigal Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $685.31.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.